Protect transplant patients with QuantiFERON
Infection prevention is critical for transplant patients
Each year, ~150,000 transplants are performed worldwide, requiring immunosuppressive therapies to prevent acute rejection.
Unfortunately, immunocompromised transplant patients are highly susceptible to post-operative infections.
These conventional and opportunistic infections are an important cause of morbidity and mortality in transplant recipients.
Are you managing infection risk?
Find freedom from CMV-related events
Cytomegalovirus (CMV) is the most common and problematic viral infection in solid organ transplant recipients.
What can you do when CMV viral load assays and CMV IgG antibody testing aren’t providing a complete picture of your patient’s immune status?
Recent international transplant guidelines state that the assessment of CMV cell-mediated immunity (CMI) can be used to inform the risk of CMV infection (1). In addition, recent interventional studies have demonstrated the potential clinical utility of using a CMV T cell immunity test in clinical practice to guide antiviral prophylaxis (2, 3).
Maintain the optimal therapeutic window for your patients
An estimated 40–70% of posttransplant mortality is attributable to the immunosuppression of the transplant recipient (6). An over-immunosuppressed patient is susceptible to opportunistic infections and drug toxicity. But an under-immunosuppressed patient can experience allograft rejection (7, 8).
Are crude markers like therapeutic drug monitoring and clinical events enough to predict your patients’ outcomes? To move towards individualized patient management, you need to complement existing methods with novel and objective markers of immune function that can aid in maintaining the optimal therapeutic window for your patients (6, 9).
Screen for TB with QuantiFERON-TB Gold Plus
Simple, consistent testing
Assess the performance of your QuantiFERON ELISA tests